Promising data from Phase 2 study in myelodyspla
Author: Michael
Company continues to advance NLRP3 neuroinflamma
Antag lands €80m to advance GIPR antagonist ap
World’s largest longevity event combines longe
Funding call for innovative scientific proposals
The Longevity Clinics panel session at this year
Prenuvo study links Type 2 diabetes to reduction
How supplements are reshaping healthspan strateg
Company lists on Nasdaq, raising $11m to take pa
A new documentary on the frontiers of longevity